Literature DB >> 21813389

Hepatitis C virus infection and biological false-positive syphilis test: a single-center experience.

Wei-Fang Zhu1, Shui-Ying Lei, Lan-Juan Li.   

Abstract

BACKGROUND: Rapid plasma regain positive and/or treponema pallidum hemagglutination negative [RPR(+)/TPHA(-)] results were designated as biologic false-positive (BFP). There are limited data about BFP reactions against syphilis in patients with hepatitis C virus (HCV) infection. This study aimed to determine the prevalence of BFP reactions for syphilis in patients with HCV infection in a large sample and assess the relationship between BFP reactions and HCV infection.
METHODS: A total of 2656 patients with positive anti-HCV and 5600 healthy control subjects were enrolled in this study. Hepatitis C serology was determined by a second generation ELISA test for HCV antibody. Syphilis serology was determined by the RPR test. Those subjects with reactive RPR positive underwent the TPHA test. Demographics and laboratory data were collected by trained clinicians.
RESULTS: Among 2656 patients, 111 (4.2%) had a reactive RPR test. Of the 111 patients who were subjected to reactive RPR test, 30 (27.0%) showed HCV(+)/RPR(+). Of 5600 healthy controls, 80 (1.4%) had a reactive RPR test. Fourteen (17.5%) controls with HCV(-)/RPR(+) had a non-reactive TPHA test. These represented 1.1% of all HCV-positive and 0.3% of all HCV-negative subjects (P<0.001). A significantly increased prevalence shown by false-positive tests for syphilis was observed in elderly HCV-seropositive patients. BFP-HCV positive group had a higher prevalence of eosinophilia. The eosinophil abnormality was compared between the patients and controls (66.7% vs 21.4%, P=0.0043). No significant results were observed in antinuclear antibodies, antiphospholipid and complement (C3, C4) (P>0.05).
CONCLUSIONS: The data of this study demonstrate that HCV infection is associated with a false-positive RPR test. In this study BFPs were significantly more common in HCV positive patients compared to HCV-negative ones. Eosinophil abnormality can be considered as a predictor for BFP. Excessive BFPs must be considered in assessing the frequency of syphilis in a HCV-positive population and the importance of the treponemal specific serologic test should be emphasized for a diagnosis of syphilis in such population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813389     DOI: 10.1016/s1499-3872(11)60067-2

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  5 in total

1.  Factors associated with distal symmetric polyneuropathies in adult Zambians: A cross-sectional, observational study of the role of HIV, non-antiretroviral medication exposures, and nutrition.

Authors:  Michelle Kvalsund; Takondwa Chidumayo; Johanna Hamel; David Herrmann; Douglas Heimburger; Amanda Peltier; Gretchen Birbeck
Journal:  J Neurol Sci       Date:  2018-02-22       Impact factor: 3.181

Review 2.  Recombinase polymerase amplification as a promising tool in hepatitis C virus diagnosis.

Authors:  Hosam Zaghloul; Mahmoud El-Shahat
Journal:  World J Hepatol       Date:  2014-12-27

3.  Comparison of Elecsys Anti-HCV II Assay With Other HCV Screening Assays.

Authors:  Dongdong Li; Siyuan Zhu; Tingting Wang; Jingna An; Lanlan Wang; Chuanmin Tao
Journal:  J Clin Lab Anal       Date:  2015-12-14       Impact factor: 2.352

Review 4.  Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection.

Authors:  Marco Ciotti; Cartesio D'Agostini; Aldo Marrone
Journal:  Gastroenterology Res       Date:  2013-10-31

5.  Improving the coverage and accuracy of syphilis testing: The development of a novel rapid, point-of-care test for confirmatory testing of active syphilis infection and its early evaluation in China and South Africa.

Authors:  Minh D Pham; Amy Wise; Mary L Garcia; Huy Van; Shuning Zheng; Yasmin Mohamed; Yan Han; Wan-Hui Wei; Yue-Ping Yin; Xiang-Sheng Chen; Wayne Dimech; Susie Braniff; Karl-Günter Technau; Stanley Luchters; David A Anderson
Journal:  EClinicalMedicine       Date:  2020-06-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.